1719 related articles for article (PubMed ID: 15780432)
41. The incretins: a link between nutrients and well-being.
Burcelin R
Br J Nutr; 2005 Apr; 93 Suppl 1():S147-56. PubMed ID: 15877888
[TBL] [Abstract][Full Text] [Related]
42. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.
Baggio LL; Drucker DJ
Treat Endocrinol; 2002; 1(2):117-25. PubMed ID: 15765627
[TBL] [Abstract][Full Text] [Related]
43. Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models.
Renner S; Blutke A; Streckel E; Wanke R; Wolf E
J Pathol; 2016 Jan; 238(2):345-58. PubMed ID: 26455904
[TBL] [Abstract][Full Text] [Related]
44. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
45. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
Escalada FJ
Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.
Graham GV; Conlon JM; Abdel-Wahab YH; Gault VA; Flatt PR
Peptides; 2018 Feb; 100():182-189. PubMed ID: 29157578
[TBL] [Abstract][Full Text] [Related]
47. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
48. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes.
Gautier JF; Choukem SP; Girard J
Diabetes Metab; 2008 Feb; 34 Suppl 2():S65-72. PubMed ID: 18640588
[TBL] [Abstract][Full Text] [Related]
49. Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential.
Holst JJ
Curr Med Chem; 1999 Nov; 6(11):1005-17. PubMed ID: 10519910
[TBL] [Abstract][Full Text] [Related]
50. Biology of incretins: GLP-1 and GIP.
Baggio LL; Drucker DJ
Gastroenterology; 2007 May; 132(6):2131-57. PubMed ID: 17498508
[TBL] [Abstract][Full Text] [Related]
51. The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 engages the glucagon-like peptide-1 incretin hormone axis to lower levels of blood glucose in db/db mice.
Meng Q; Chepurny OG; Leech CA; Pruekprasert N; Molnar ME; Collier JJ; Cooney RN; Holz GG
Diabetes Obes Metab; 2022 Jul; 24(7):1255-1266. PubMed ID: 35293666
[TBL] [Abstract][Full Text] [Related]
52. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
Yabe D; Seino Y
Prog Biophys Mol Biol; 2011 Nov; 107(2):248-56. PubMed ID: 21820006
[TBL] [Abstract][Full Text] [Related]
53. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
54. GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion.
Cani PD; Holst JJ; Drucker DJ; Delzenne NM; Thorens B; Burcelin R; Knauf C
Mol Cell Endocrinol; 2007 Sep; 276(1-2):18-23. PubMed ID: 17681422
[TBL] [Abstract][Full Text] [Related]
55. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions.
Nauck MA; Meier JJ
Lancet Diabetes Endocrinol; 2016 Jun; 4(6):525-36. PubMed ID: 26876794
[TBL] [Abstract][Full Text] [Related]
56. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.
Drucker DJ
Diabetes; 2013 Oct; 62(10):3316-23. PubMed ID: 23818527
[TBL] [Abstract][Full Text] [Related]
57. On the physiology of GIP and GLP-1.
Holst JJ
Horm Metab Res; 2004; 36(11-12):747-54. PubMed ID: 15655703
[TBL] [Abstract][Full Text] [Related]
58. Incretin actions beyond the pancreas: lessons from knockout mice.
Yabe D; Seino Y
Curr Opin Pharmacol; 2013 Dec; 13(6):946-53. PubMed ID: 24095602
[TBL] [Abstract][Full Text] [Related]
59. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
[TBL] [Abstract][Full Text] [Related]
60. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
Gefel D; Barg Y; Zimlichman R
Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
